B
BioLine RX Ltd
TASE:BLRX
BioLine RX Ltd
TASE:BLRX
Price:
1.6
ILS
6.67%
Market Closed
Market Cap:
₪36.7m
Relative Value
The Relative Value of one BLRX stock under the Base Case scenario is 3.74 ILS. Compared to the current market price of 1.6 ILS, BioLine RX Ltd is Undervalued by 57%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
BLRX
Relative Value
Base Case
3.74
ILS
Undervaluation 57%
B
Multiples Across Competitors
BLRX Competitors Multiples
BioLine RX Ltd Competitors
BioLine RX Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| IL |
B
|
BioLine RX Ltd
TASE:BLRX
|
36.7m ILS | 0.9 | -3.9 | 0.7 | 0.6 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 643 258.8 | -159 901.4 | -194 171.3 | -191 955.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
400.4B USD | 6.7 | 170.1 | 16.5 | 23.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.5B USD | 5.1 | 26.4 | 18.8 | 18.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
177.3B USD | 6.2 | 22.2 | 15.1 | 15.1 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
120.1B USD | 10.1 | 32.2 | 23.6 | 24.7 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 094 | -534.3 | -581.8 | -566.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.4B USD | 5.6 | 17.8 | 15 | 17.1 | |
| AU |
|
CSL Ltd
ASX:CSL
|
86.7B AUD | 3.9 | 20.1 | 13.4 | 16.8 | |
| NL |
|
argenx SE
XBRU:ARGX
|
43.5B EUR | 14.5 | 34.2 | 58.4 | 60.1 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.2 | -61.8 | -66.7 | -60.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
